PepJunkie Home of the Peptonauts
More
HomeThe PulseAtlasDiscussHunter-GathererResearchProfileSearch

Research

Cagrilintide — living evidence map

The Atlas page holds the claims; this is how its evidence evolved.

Summary

Cagrilintide is a long-acting analogue of amylin, a pancreatic hormone that induces satiety; in a 26-week phase 2 trial in 706 adults with overweight or obesity, once-weekly doses reduced body weight by 6.0% to 10.8% against 3.0% on placebo, with more nausea. · pmid:34798060

In a 68-week phase 3a trial in 3,417 adults, cagrilintide combined with semaglutide reduced body weight by 20.4% against 3.0% on placebo. · pmid:40544433

Identity

PubChem CID 171397054: Cagrilintide, C194H312N54O59S2, 4409 g/mol. · pubchem:171397054

CAS registry number 1415456-99-3. · pubchem:171397054

Where the evidence actually sits

Established50%
Emerging50%

Proportion of the 2 claims about Cagrilintide standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.

Living evidence history

Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. (2021) · emergingCoadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. (2025) · established20212025

2 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.

Structure

No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for Cagrilintide yet.

Dose evidence, rung by rung

A studied human dose exists on file. Open the rung: the dose is the paper's, in its context, never PepJunkie's.

  1. Approved-label dose · a resolved regulatory document names a labelled dose

    nothing resolved on this rung

  2. Studied human doses · resolved human studies at the established tier
    • Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. · pmid 40544433 · 2025
  3. Observational evidence · resolved human data at the emerging tier: thin, or contested
    • Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. · pmid 34798060 · 2021
  4. Community-reported protocols · protocol propositions from distinct members, counted once per human

    nothing resolved on this rung

  5. Preclinical evidence · resolved animal, cell or mechanistic work

    nothing resolved on this rung

2 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.